Rapid COVID Testing: How Bangladesh Built Its Pandemic Response Infrastructure

March 2020: One Lab, 170 Million People

When Bangladesh confirmed its first three COVID-19 cases on March 8, 2020, the country had exactly one laboratory capable of testing for the virus: the Institute of Epidemiology Disease Control and Research (IEDCR), located in Mohakhali, Dhaka. For a country of 170 million people — one of the most densely populated on earth — this was not a diagnostic infrastructure. It was a bottleneck. The question that defined Bangladesh's pandemic response over the next two years was whether that bottleneck could be broken fast enough to matter.

The answer was partial. Bangladesh built a testing network where none had existed. It scaled from one lab to dozens of PCR facilities within months, approved antigen-based rapid diagnostic testing in September 2020, deployed community health workers to low-income Dhaka neighborhoods with test kits in 2021, and produced the country's first domestically manufactured RT-PCR kit by January of that year. In the process, it generated a body of scientific evidence — including peer-reviewed clinical trials conducted by icddr,b, IEDCR, and university researchers — that documented what worked and what didn't in a low-resource, high-density setting. That evidence now belongs to the global public health literature. What Bangladesh does with it, and whether the institutions that produced it can sustain their capacity, is the harder question.

The Race to Build a Testing Network

From a single PCR lab in March 2020, the government scaled aggressively through two parallel tracks: expanding the PCR network and introducing faster, cheaper antigen testing. By mid-2021, the PCR network had grown to cover all 64 districts of Bangladesh. The expansion relied on GeneXpert machines — originally deployed for tuberculosis diagnosis — being repurposed for COVID-19 testing, alongside dedicated RT-PCR capacity in government hospitals, academic labs, and eventually private facilities.

The antigen testing track moved more slowly, in part because of legitimate scientific debate about its accuracy. WHO issued interim guidance on antigen rapid diagnostic tests in September 2020, and Bangladesh's Ministry of Health followed with a circular permitting antigen testing the same month, specifically at government hospitals, district hospitals, and PCR labs. The guidance was clear: antigen-positive patients should be isolated immediately; antigen-negative patients with symptoms should be retested by RT-PCR or GeneXpert for confirmation. This two-step protocol acknowledged the trade-off at the heart of rapid testing — speed versus sensitivity.

The numbers scaled quickly once the infrastructure was in place. Starting with 10 antigen testing centers in December 2020, the government reached 40 within two weeks and 73 by March 2021. WHO provided 240,000 antigen-based rapid diagnostic tests worth approximately $1.16 million to ensure coverage in districts where PCR lab access was limited. The goal was geographic equity: ensuring that rural areas and hard-to-reach communities that had seen COVID-19 cases surge without diagnosis capacity could access at least some testing.

What the Science Said About Accuracy

Bangladesh was unusual in generating rigorous peer-reviewed clinical evidence about its own rapid testing rollout rather than simply importing global guidance. Researchers at icddr,b, IEDCR, and the Institute for Developing Science and Health Initiatives (ideSHi) conducted a clinical evaluation of the Standard Q COVID-19 Ag Test across 900 suspected COVID-19 patients between December 2020 and April 2021. Published in the journal Heliyon, the study found overall sensitivity of 85 percent and specificity of 100 percent compared to RT-PCR as the gold standard. Critically, for patients tested within the first five days of symptom onset — when viral load is typically highest — sensitivity reached 85.9 percent.

A separate community-based study published in BMJ Open evaluated rapid antigen testing conducted by community health workers in low-income Dhaka neighborhoods between May and July 2021, just as the Delta variant was surging. Using nasal swabs, community health workers achieved sensitivity of 68 percent and specificity of 98 percent. The sensitivity figure was lower than in clinical settings — expected, given the community context and varying symptom stages — but the study's more important finding was about deployment: having community health workers administer tests at the household level dramatically increased the number of people from marginalized communities who actually got tested. "People in these communities were keen to be tested as results were returned immediately in the privacy of their own household," the researchers noted, adding that familiarity and trust of community health workers contributed to uptake.

A third study published in the American Journal of Tropical Medicine and Hygiene evaluated the BD Veritor and Standard Q rapid antigen tests against RT-PCR across 130 symptomatic and 130 asymptomatic adults, finding sensitivity of 70 percent (BD Veritor) and 63 percent (Standard Q) in symptomatic individuals. The consistency across studies pointed to a stable picture: antigen tests in Bangladesh performed within the range documented globally, with sensitivity adequate for clinical triage but not for ruling out infection in symptomatic individuals without confirmatory testing.

The Cost Argument That Drove Adoption

Bangladesh's rapid antigen testing expansion was ultimately driven not just by scientific evidence but by economics. The cost differential between rapid antigen tests and PCR was decisive in a resource-constrained setting. Researchers modeling testing strategy under fixed budgets estimated rapid antigen tests at approximately $5 per test versus $30 for RT-PCR. At high prevalence — and Bangladesh's test positivity rate exceeded 60 percent at the peak of the Beta and Delta waves — antigen testing provided substantially more case identification per dollar spent than PCR alone, even accounting for lower sensitivity.

This arithmetic made the case for antigen testing as a population-level screening tool, even if individual-level confirmation still required PCR. For Bangladesh, where household incomes are low and out-of-pocket health spending is already a major driver of poverty, the difference between a BDT 250-300 rapid test (the price point that Gono Shasthaya Kendra had targeted for its domestically produced kit) and a several-thousand-taka PCR test was the difference between testing that reached most of the population and testing that reached mainly urban, higher-income households.

The domestic manufacturing milestone mattered symbolically as well as practically. OMC Healthcare received DGDA approval for Bangladesh's first domestically produced COVID-19 RT-PCR kit in January 2021, with the company reporting initial capacity of 40,000 to 50,000 kits per day. The approval demonstrated that Bangladesh's biotech sector could respond to a public health emergency with domestic production — reducing dependence on imported kits at a moment when global supply chains were under strain. Whether that capacity has been sustained post-pandemic is a question the health system has not yet answered publicly.

Governance Gaps That Testing Could Not Solve

Bangladesh's testing expansion was real, but it existed within a governance framework that researchers consistently found inadequate for the scale of the challenge. A 2024 scoping review published in a peer-reviewed health policy journal and based on eleven studies of Bangladesh's COVID-19 response described it as "delayed, slow, and ambiguous, reflecting poorly on its governance." The review identified specific failures: inadequate airport screening of returnees from Italy in the early weeks, unsupervised home quarantine that was "largely ineffective," and — directly relevant to testing — failures in "timely and equitable COVID-19 testing" and "logistics and procurement."

These are not abstract criticisms. The gap between having testing infrastructure and ensuring equitable access to it is one that Bangladesh has consistently struggled with in its health system, long before COVID-19. High out-of-pocket payments, inequitable access between urban and rural populations, and shortage of skilled providers are structural features of the system that WHO has documented in successive country cooperation strategies. COVID-19 testing exposed these features clearly: the expansion of PCR labs happened faster in divisional cities than in rural upazilas; the antigen testing rollout prioritized district-level hospitals before sub-district facilities; and the community health worker deployment in Dhaka slums was a research project, not a national program.

The positive case for what Bangladesh achieved should be stated plainly: starting from one lab, the country built a nationwide testing network in roughly twelve months, produced peer-reviewed evidence about what worked in its specific context, developed a domestic testing kit manufacturing capacity, and improved infection prevention and control (IPC) standards across 120 health facilities — from 8 percent compliance on IPC personnel to 100 percent, and from 22 percent compliance on training to 100 percent, according to WHO's scorecard monitoring in Cox's Bazar. These are real accomplishments. The critical case should be stated equally plainly: the governance framework that surrounded these technical achievements was inadequate, and the structural vulnerabilities that made equitable access difficult have not been resolved.

What Preparedness Looks Like After COVID

The institutional architecture that Bangladesh built during COVID-19 now forms the foundation of its pandemic preparedness for whatever comes next. CDC has worked in Bangladesh for 50 years and has supported IEDCR and icddr,b on nationwide respiratory virus surveillance since the National Influenza Center was established in 2007. That surveillance system — now covering influenza, SARS-CoV-2, and other respiratory pathogens in general populations, hospitals, and live bird markets — provides the early warning function that Bangladesh's COVID-19 response critically lacked in January and February 2020. The IEDCR national public health emergency operations center, linked to national rapid response teams, exists today in a form it did not in early 2020.

The H5N1 avian influenza situation globally — with the 2024 strain showing expanded mammalian transmission documented in cattle, cats, and humans in the United States — is the kind of threat this surveillance architecture is meant to detect early. Bangladesh has experienced multiple H5N1 outbreaks in poultry, and the live bird markets that CDC monitors are exactly the interface where novel variants can emerge. Whether Bangladesh's diagnostic infrastructure can respond to a new respiratory pathogen faster than it did to SARS-CoV-2 depends on three things that remain uncertain: political will to act on early signals before confirmed cases accumulate, pre-negotiated supply chains for diagnostic tests that don't rely on global markets during a global emergency, and governance capacity to translate technical infrastructure into equitable access at speed.

The lesson that Bangladesh's COVID-19 testing experience most clearly teaches is not a technical one. The sensitivity of Standard Q versus BD Veritor versus RT-PCR in Dhaka slums is documented. What is not documented — and what requires political decisions, not laboratory research — is how a health system with known structural inequities ensures that the next diagnostic tool reaches the population that needs it before the outbreak has already peaked. Bangladesh spent the first months of COVID-19 building that answer from scratch. The infrastructure now exists to do better. Whether it will is a governance question, not a science question.

win-tk.org is a wintk publication covering global affairs and culture for Bangladeshi and South Asian audiences.